Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Daily capsule for patients with skin cancer

Patients with a rare form of skin cancer could now benefit from first-of-a-kind once daily capsule


Erivedge® (vismodegib), a new medicine that has been shown to help patients with a disfiguring and potentially life-threatening form of skin cancer, is now registered for use in New Zealand.

Erivedge is a first-in-class Hedgehog Pathway Inhibitor that helps shrink disfiguring or potentially life-threatening lesions in advanced skin cancer

AUCKLAND – 23 April 2014: From today, adult New Zealanders with metastatic basal cell carcinoma (mBCC) or locally advanced BCC (laBCC) where treatment with surgery or radiotherapy is inappropriate, could benefit from Erivedge®. 1 This makes Erivedge, a capsule taken once daily, the only registered medicine for advanced BCC (aBCC, is comprised of mBCC and laBCC) fulfilling an unmet medical need in this group of patients.1

BCC is the most common type of skin cancer in the world. 2 It is estimated that in 2006 there were 43,900 New Zealanders diagnosed with BCC and that this number is growing year on year.

BCC forms the majority (65% - 75%) of non-melanoma skin cancers (NMSC). In 2006, NMSC was estimated to have incurred NZ$51.4 million in healthcare costs (excluding GST) and NZ$6.7 million in lost production.

BCC is considered curable when confined to the skin.

However, in some cases the disease will invade surrounding tissue (locally advanced) or spread to other parts of the body (metastatic BCC) in a manner that cannot be effectively treated with surgery or radiation.
Dr Richard Martin, Cutaneous Surgical Oncologist, says that advanced basal cell carcinoma can be highly disfiguring and can significantly impact quality of life.

“Until now, there have not been any active treatment options available for patients who are not appropriate for surgery or radiotherapy. Erivedge, which has been shown to shrink tumours, addresses this unmet need and is a welcome new treatment option for patients with advanced BCC,” said Dr Martin.

An independent review facility assessment found that Erivedge shrank visible lesions in 43 percent (27/63) of patients with locally advanced BCC inappropriate for surgery or radiotherapy and shrank tumours in 30 percent (10/33) of those with metastatic BCC.

An application for funding will be submitted to PHARMAC in due course. In the interim, Erivedge will be available for private purchase .

-ENDS-

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Housing Policy: Auckland Densification As Popular As Ebola, English Says

Finance Minister Bill English said calls by the Reserve Bank Governor for more densification in Auckland’s housing were “about as popular in parts of Auckland as Ebola” would be. More>>

ALSO:

Crown Accounts: NZ Government Deficit Smaller Than Expected In First Half

The New Zealand government's operating deficit was smaller than expected in the first six months of the financial year, as the consumption and corporate tax take rose ahead of forecast in December, having lagged estimates in previous months. More>>

ALSO:

Fruit & Veg Crackdown: Auckland Fruit Fly Find Under Investigation

The Ministry for Primary Industries (MPI) is investigating a find of a single male Queensland fruit fly in a surveillance trap in the Auckland suburb of Grey Lynn... MPI has placed legal controls on the movement of fruit and some vegetables outside of a defined circular area which extends 1.5km from where the fly was trapped in Grey Lynn. More>>

ALSO:

Scoop Business: Westpac NZ Reaches $2.97M Swaps Settlement

Westpac Banking Corp’s New Zealand unit has agreed to pay $2.97 million in a settlement with the Commerce Commission over the way the bank sold interest rate swaps to farmers between 2005 and 2012. More>>

ALSO:

Going Dutch: Fonterra Kicks Off $144M Partnership With Dutch Cheese Maker

Fonterra Co-operative Group, the world’s largest dairy exporter, has commissioned a new dairy ingredients plant in Heerenveen, in the north of the Netherlands, its first wholly-owned and operated ingredients plant in Europe. More>>

ALSO:

Scoop Business: NZ Retail Sales Beat Estimates

New Zealand retail sales rose more than expected in the fourth quarter, led by vehicle-related transactions, food and beverages, adding to evidence that cheap credit and a growing jobs market are encouraging consumers to spend. More>>

ALSO:

Delivery Cuts Go Ahead: 'Government Money Grab' From NZ Post

"It's a money grab by the Government as the shareholder of New Zealand Post" says Postal Workers Union advocate Graeme Clarke about the changes announced by NZ Post. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news